|
|
Ad hoc ( § 15 WpHG) : Epigenomics AG Licenses Several Key Technologies to OncoMethylome Sciences S.A.
 |
 |
| Date: Monday, 14.01.2008 |
|
| Berlin, Germany, January 11, 2008, 08:00 CET |
|
Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) has entered into a broad technology licensing agreement with OncoMethylome Sciences S.A. (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today. Under the terms of the agreement, OncoMethylome obtained worldwide non-exclusive rights to several of Epigenomics’ proprietary core technologies such as its MethyLight portfolio for the sensitive and quantitative detection of DNA methylation for in vitro diagnostic product development and commercialization. Further, OncoMethylome obtained rights to HeavyMethyl® technology, plus certain microarray-based technologies for DNA methylation analysis. In return for the licenses, Epigenomics will receive an up-front payment and is eligible for royalties to be paid on any eventual commercial exploitation of the technologies by OncoMethylome and any of its partners who choose to sublicense such technology. Both companies continue to independently develop their own products and biomarker licenses have not been granted.
Further details and financial terms of the agreement have not been released.
End of ad hoc
For further detail, please see today's joint press release by Epigenomics AG and OncoMethylome Sciences S.A. which is available at www.epigenomics.com.
###
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
|
|
| back |
|
top of the page
|
